FAM13A

Across TCGA pan-cancer cohorts, FAM13A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FAM13A data layer compared with 19 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FAM13A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FAM13A expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where FAM13A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	IV	0.781	0.220	.017	13	view →
LUAD	DFS	Quartile	All	0.411	0.762	.007	10	view →
PDAC	OS	Quartile	II,III,IV	0.239	0.431	.040	4	view →
LSCC	DFS	Quartile	All	0.695	0.916	.015	4	view →
UCEC	DFS	Median	All	0.960	0.839	.032	2	view →
HNSC	OS	Median	All	0.823	1.000	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FAM13A–CCRCC (DFS)

Open the CCRCC breakdown →